Financial News · Live Terminal

Page 36 of 299

Morgan Stanley Reduces Campari Group PT, Keeps at Equalweight

Morgan Stanley on Tuesday decreased the price target for Italian alcoholic beverages company Davide Campari-Milano (CPR.MI), d/b/a Campari Group, to 6.10 euros from 6.60 euros and maintained the equal weight rating on the stock.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Financial News · Live Terminal

Morgan Stanley Reduces Campari Group PT, Keeps at Equalweight

EFG-Hermes Brokerage Lifts Gas Arabian Services PT, Keeps at Buy

Shore Capital Downgrades Oxford Instruments to Hold, Boosts PT

Cantor Fitzgerald Downgrades Nuvalent to Neutral From Overweight

Wedbush Downgrades Nuvalent to Neutral From Outperform, Trims Price Target to $124 From $125

Piper Sandler Downgrades Nuvalent to Neutral From Overweight, Adjusts PT to $124 From $128

Argus Research Downgrades Prudential Financial to Hold From Buy

B. Riley Raises Price Target on Tango Therapeutics to $35 From $21, Keeps Buy Rating

CN Rail Price Target Raised to $182 at CIBC

B. Riley Initiates NioCorp Developments at Buy With $12 Price Target

Keefe Bruyette & Woods Upgrades Toll Brothers to Outperform From Market Perform, Lifts Price Target to $161 From $158

Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76

JPMorgan Upgrades PAR Technology to Neutral From Underweight, Lifts Price Target to $16 From $12

Northland Initiates VEON at Outperform With $70 Price Target

Canaccord Genuity Upgrades FuelCell Energy to Buy From Hold, Raise Price Target to $30 From $12

Oppenheimer Downgrades Ingredion to Market Perform From Outperform

Oppenheimer Initiates Precision BioSciences at Outperform

Oppenheimer Initiates LSI Industries at Outperform With $30 Price Target

Barclays Initiates WhiteFiber at Equalweight With $27 Price Target

Raymond James Initiates FrontView REIT at Strong Buy With $22 Price Target

Morgan Stanley Reduces Campari Group PT, Keeps at Equalweight

EFG-Hermes Brokerage Lifts Gas Arabian Services PT, Keeps at Buy

Shore Capital Downgrades Oxford Instruments to Hold, Boosts PT

Cantor Fitzgerald Downgrades Nuvalent to Neutral From Overweight

Wedbush Downgrades Nuvalent to Neutral From Outperform, Trims Price Target to $124 From $125

Piper Sandler Downgrades Nuvalent to Neutral From Overweight, Adjusts PT to $124 From $128

Argus Research Downgrades Prudential Financial to Hold From Buy

B. Riley Raises Price Target on Tango Therapeutics to $35 From $21, Keeps Buy Rating

CN Rail Price Target Raised to $182 at CIBC

B. Riley Initiates NioCorp Developments at Buy With $12 Price Target

Keefe Bruyette & Woods Upgrades Toll Brothers to Outperform From Market Perform, Lifts Price Target to $161 From $158

Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76

JPMorgan Upgrades PAR Technology to Neutral From Underweight, Lifts Price Target to $16 From $12

Northland Initiates VEON at Outperform With $70 Price Target

Canaccord Genuity Upgrades FuelCell Energy to Buy From Hold, Raise Price Target to $30 From $12

Oppenheimer Downgrades Ingredion to Market Perform From Outperform

Oppenheimer Initiates Precision BioSciences at Outperform

Oppenheimer Initiates LSI Industries at Outperform With $30 Price Target

Barclays Initiates WhiteFiber at Equalweight With $27 Price Target

Raymond James Initiates FrontView REIT at Strong Buy With $22 Price Target